|
|
|
Volumn 8, Issue 5, 2010, Pages 313-314
|
|
Cost of new oncology drugs
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ARTICLE;
CANCER CHEMOTHERAPY;
CONSENSUS DEVELOPMENT;
COST CONTROL;
COST EFFECTIVENESS ANALYSIS;
COST OF ILLNESS;
DRUG APPROVAL;
DRUG COST;
DRUG MANUFACTURE;
DRUG RESPONSE;
FEASIBILITY STUDY;
GOVERNMENT REGULATION;
HEALTH CARE QUALITY;
HEALTH INSURANCE;
HUMAN;
LUNG CANCER;
OFF LABEL DRUG USE;
ONCOLOGY;
PANCREAS CANCER;
PATIENT CARE;
PHYSICIAN ATTITUDE;
PHYSICIAN INCOME;
QUALITY OF LIFE;
UNITED STATES;
DRUG DESIGN;
ECONOMICS;
FEE;
HEALTH CARE POLICY;
MEDICAL FEE;
ANTINEOPLASTIC AGENTS;
DRUG APPROVAL;
DRUG DESIGN;
FEE-FOR-SERVICE PLANS;
FEES, PHARMACEUTICAL;
HEALTH CARE REFORM;
HUMANS;
UNITED STATES;
|
|
EID: 77953682053
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (1)
|
|
References (3)
|
